Target intelligence / Profile preview

Peptidoglycan D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall component, Peptidoglycan precursor, Dipeptide
01

Overview

The Peptidoglycan D-alanyl-D-alanine terminus is a critical structural component of the bacterial cell wall precursor, specifically found at the C-terminal end of the pentapeptide chain (StatPearls, 2023). This dipeptide motif serves as the substrate for transpeptidase enzymes (penicillin-binding proteins) that catalyze the cross-linking of peptidoglycan layers, providing mechanical strength to the bacterial cell wall (NCBI, 2022). It is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin, which bind to the D-Ala-D-Ala moiety via a network of five hydrogen bonds (PubMed, 2021). By sequestering this terminus, these drugs sterically hinder the enzymatic assembly of the cell wall, leading to bacterial cell lysis and death (Nature, 2020). This target is predominantly relevant in Gram-positive bacteria, as the outer membrane of Gram-negative bacteria typically prevents glycopeptide penetration. Resistance to drugs targeting this site often involves the metabolic reprogramming of the cell wall synthesis pathway to replace the terminal D-alanine with D-lactate or D-serine, significantly reducing drug binding affinity (Microbiology Society, 2019).

Other names
D-alanyl-D-alanineD-Ala-D-Ala dipeptidePeptidoglycan precursor C-terminusUDP-N-acetylmuramyl-pentapeptide terminus
02

Mechanism of action

Glycopeptide antibiotics bind with high affinity to the D-alanyl-D-alanine C-terminus of the peptidoglycan precursor, sterically inhibiting the transglycosylation and transpeptidation reactions required for cell wall cross-linking (StatPearls, 2023; PubMed, 2021).

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingStructural integrity maintenance
04

Disease associations

Bacterial infectionGram-positive bacterial infectionSepsis
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndromeAntibiotic resistance (VRE, VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

VanA geneVanB geneMinimum Inhibitory Concentration (MIC)D-Ala-D-Lac substitution

Beyond the preview

Go deeper on Peptidoglycan D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call